Retatrutide Research Protocol: Evidence & Vial Reference

Retatrutide (LY3437943) is an investigational triple GLP-1/GIP/glucagon receptor agonist. It has been studied in supervised clinical trials but is not an approved medicine. The phase 2 obesity trial used fixed-dose and target-dose arms with gradual escalation every 4 weeks—not automatic weekly increases. For research purposes only.

Research classification: Investigational · published human trial. The Retatrutide 10 mg vial label reports nominal content; it does not state a suitable amount for human use.

In test subjects, retatrutide activates GLP-1, GIP and glucagon receptors, combining incretin-driven insulin secretion and satiety with glucagon-driven energy expenditure. Half-life ~6 days supports once-weekly research dosing.

Mechanistic findings and early experiments do not by themselves establish clinical efficacy, an approved treatment cycle or equivalence between suppliers' formulations. Interpret claims in the context of the specific experimental model and references.

A published phase 2 study in NEJM included a fixed 1 mg arm and target-dose arms that started at 2 mg or 4 mg. Escalation in target-dose arms occurred every four weeks; there is no approved human dosing schedule for retatrutide. The study formulation and monitored trial participants are not interchangeable with research-vial products.

For the existing schedule, its evidence caveats and the concentration calculator, see the Retatrutide protocol and vial reference. Figures displayed there are research context, not a personalised prescription.

An exact-matching Peak Peptides Australia 10 mg vial is shown on the research reference page. The product is supplied for in-vitro research, not administration.

Reconstitution cannot be inferred from vial strength alone. Confirm the exact compound, lot, expected appearance, compatible sterile diluent, final volume, transfer method and discard/storage period from validated formulation documentation. BAC water and a 28-day period are not universal defaults. See the illustrated product-specific preparation guide and the abnormal-solution safety guide.

View Peak Peptides Australia's research-only listing and confirm its current labelled strength.

• Jastreboff AM et al. Triple-hormone-receptor agonist Retatrutide for obesity. NEJM 2023 — NEJM

For clinical decisions, consult a qualified professional and the product information for an approved formulation. Research-only supplier material must not be injected or used to treat a condition. Explore the A–Z research directory to compare evidence categories.